Concurrent 8: Clinical Research and Epidemiology

Date: Saturday 25 September 2021
Time: 09.20-10.20 CET


Concurrent talks are 8 minutes plus 2 minutes discussion


Kaisa Tasanen (Oulu), Remco van Doorn (Leiden)




ORAL 055 (POSTER 038)

Differences in clinical features and comorbid burden between HLA-C*06:02 carrier groups in more than 9,000 people with psoriasis

Konstantinos Douroudis2Ravi Ramessur2, Nick Dand1, 4, Catherine Smith2, 3, Michael Simpson1

1Department of Medical and Molecular Genetics, School of Basic & Medical Biosciences, Faculty of Life Sciences & Medicine, King’s College London, London, United Kingdom, 2St John’s Institute of Dermatology, School of Basic & Medical Biosciences, Faculty of Life Sciences & Medicine, King’s College London, London, United Kingdom, 3St John’s Institute of Dermatology, Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom, 4Health Data Research UK, London, United Kingdom


ORAL 056 (POSTER 037)

Efficacy and safety of tirabrutinib, highly selective Bruton’s tyrosine kinase inhibitor, for oral treatment of pemphigus: a multicenter, open-label, uncontrolled, single-arm phase 2 study

Jun Yamagami1, Hideyuki Ujiie2, Yumi Aoyama3, Norito Ishii4, Chiharu Tateishi5, Akira Ishiko6, Tomoki Ichijima7, Shunsuke Hagihara7, Koji Hashimoto8, Masayuki Amagai1

1Keio University School of Medicine, Tokyo, Japan, 2Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, 3Kawasaki Medical School, Okayama, Japan, 4Kurume University School of Medicine, Kurume, Japan, 5Osaka City University Graduate School of Medicine, Osaka, Japan, 6School of Medicine, Faculty of Medicine, Toho University, Tokyo, Japan, 7Ono Pharmaceutical Co., Ltd., Osaka, Japan, 8Ehime University School of Medicine, Matsuyama, Japan


ORAL 057 (POSTER 040)

Drug survival of biologics in patients with early vs. late onset psoriasis: an analysis from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)

Oras Alabas

Centre for Dermatology Research, The University of Manchester, Manchester, United Kingdom


ORAL 058 (POSTER 046)

A computational model suggested potential therapies for dupilumab poor responders in atopic dermatitis

Takuya Miyano1, Alan D Irvine2, 3, Reiko J. Tanaka1

1Department of Bioengineering, Imperial College London, London, United Kingdom, 2Pediatric Dermatology, Children’s Health Ireland at Crumlin, Dublin, Ireland, 3Clinical Medicine, Trinity College Dublin, Dublin, Ireland


ORAL 059 (POSTER 049)

Janus Kinase 1 Inhibitor INCB054707 Modulates Disease-Associated Markers and Pathways in Hidradenitis Suppurativa

Huiqing Liu1, Timothy C. Burn1, Jeffery Jackson1, Michael Howell2, Leandro L. Santos1, Afsaneh Alavi3, Susan Smith1

1Incyte Corporation, Wilmington, Delaware, United States, 2DermTech Inc, La Jolla, California, United States, 3Mayo Clinic, Rochester, Minnesota, United States


ORAL 060 (POSTER 045)

NF-κB phosphorylation in type-2 dendritic cells at baseline is a blood predictive biomarker of clinical response to adalimumab in psoriasis

Rosa Andres Ejarque1Paola Di Meglio1, PSORT Consortium2

1St John’s Institute of Dermatology, King’s College London, London, United Kingdom, 2The University of Manchester, Manchester, United Kingdom